Large-scale sequencing approaches have shown that chronic lymphocytic leukemia (CLL) is composed of a mosaic of leukemic subpopulations, each of which is defined by distinct genetic lesions. [1] [2] [3] [4] The application of ultra-deep-next generation sequencing (NGS) to track TP53 mutated subclones in CLL has provided a proof-of-concept that small tumor cell populations of very low clonal abundance can drive the overall disease course and may represent informative and highly sensitive biomarkers of chemorefractoriness. 5 In addition to TP53, other cancer genes known to be recurrently mutated in CLL and significantly associated with poor survival include NOTCH1, SF3B1, and BIRC3. 6 The clinical impact of mutations in the NOTCH1, SF3B1, and BIRC3 genes has been so far documented in CLL series investigated by conventional sequencing, that has a sensitivity limit of 10-15%. Here we assessed the frequency, prognostic impact and evolution during CLL course of small subclones mutated in the NOTCH1, SF3B1, and BIRC3 genes.
The study population was a consecutive series of 304 newly diagnosed CLL patients (Table   1S ) who were prospectively registered in the Amedeo Avogadro University CLL-database. 5 CLL diagnosis was according to IWCLL-NCI criteria. Median follow-up of alive patients was 7 years.
Patients provided informed consent in accordance with local IRB requirements and Declaration of Helsinki. The study was approved by the Ethical Committee of the Ospedale Maggiore della Carità di Novara associated with the Amedeo Avogadro University of Eastern Piedmont (Protocol Code 59/CE; Study Number CE 8/11).
We applied an ultra-deep-NGS strategy coupled with a robust bioinformatic algorithm for highly sensitive detection of small mutated subclones in the NOTCH1, SF3B1, and BIRC3 genes.
NOTCH1, SF3B1
, and BIRC3 mutation hotspots (Table 2S) were investigated on genomic DNA extracted from peripheral blood mononuclear cell samples collected at CLL diagnosis, progression requiring treatment, relapse, and last follow-up. In all cases, the fraction of tumor cells corresponded to 70-98% as assessed by flow cytometry. Ultra-deep-NGS was performed using the 454 chemistry, was based on amplicon libraries, and was tailored at a ~2000-fold coverage per 3 amplicon (average coverage: 2437x, range 1003x-8584x). A previously developed bioinformatic algorithm was applied to call non-silent variants out of background NGS noise. 5 The sensitivity of the ultra-deep-NGS approach allowed to detect mutant allele fractions down to 0.3% (3 mutant alleles in a background of ~1000 wild type alleles) with a 95% confidence interval of 0.2-0.5%.
Variant calling by the algorithm was validated by Sanger sequencing or, if the variant was below the sensitivity threshold of Sanger sequencing, by both duplicate ultra-deep-NGS and allele specific PCR (AS-PCR) ( Figure 1S ). To account for tumor representation, the frequency of the mutant alleles provided by ultra-deep-NGS was corrected for the proportion of CD19+/CD5+ cells in each sample. Overall survival (OS) from diagnosis was the primary endpoint and was measured from date of initial presentation to date of death from any cause (event) or last follow-up (censoring).
Survival analysis was performed by Kaplan-Meier method. 7 To identify the optimal cut-off of the variant allele frequency to predict CLL OS we used the outcome-driven maximally selected rank statistics implemented in the maxstat package of R. 8 Figure 1A -1C). NOTCH1 mutations were more represented in the leukemic cell population ( Figure 2S ) and, therefore, more frequently detectable by Sanger sequencing than SF3B1 and BIRC3 variants, consistent with the notion that NOTCH1 4 mutations are an early event, while SF3B1 and BIRC3 lesions are late events in CLL evolution. 2, 9, 10 These data indicate that a fraction of SF3B1, BIRC3, and to a lesser extent, NOTCH1 mutations may be restricted to small subclones not detectable by conventional sequencing at the time of CLL presentation.
The molecular spectrum (i.e. type and hot spot distribution) of small subclonal mutations of NOTCH1, SF3B1, and BIRC3 was highly consistent with that of variants that were detectable by Sanger sequencing in CLL ( Figure 1D-1F ). These data indicate that small subclonal mutations of NOTCH1, SF3B1, and BIRC3 do not represent biologically irrelevant random passenger events, but instead are predicted to have an impact on the proteins similar to that of clonal variants.
The OS of patients harboring small subclonal mutations of NOTCH1, SF3B1, or BIRC3 was not significantly different from that of wild type patients (Figure 2A-2C ), even after adjusting for confounding factors (Table 6S ). The study, however, was not fully powered to support noninferiority. Conversely, patients harboring small subclonal mutations of NOTCH1, SF3B1, or BIRC3 showed a trend towards a longer OS than patients having a mutation that was detectable by
Sanger sequencing (Figure 2A-2C) . Consistently, outcome-driven approaches documented that NOTCH1, SF3B1, and BIRC3 mutations should be represented in at least 25%, 35% and 1% of the alleles, respectively, to have the maximum impact on CLL OS ( Figure 3S ). Application of these approaches to TP53 mutations failed in identifying a clear cut off, suggesting that, at variance with NOTCH1, SF3B1, and BIRC3 mutations, TP53 lesions are relevant to the outcome of CLL independent of their abundance ( Figure 4S ).
5
Longitudinal ultra-deep-NGS of sequential samples was carried out in 7 cases harboring small subclonal NOTCH1 mutations (including 2 patients that required therapy and 5 that underwent watch and wait), in 12 cases harboring small subclonal SF3B1 mutations (including 4 patients that required therapy and 8 that underwent watch and wait), and in 6 cases harboring small subclonal BIRC3 mutations (including 4 patients that required therapy and 2 that underwent watch and wait). By longitudinal analysis, the abundance of small subclonal mutations of NOTCH1,
SF3B1, and BIRC3 did not significantly change upon watch and wait, with only scattered mutations displaying an outgrowth ( Figure 3 ; Figure 5S ). Upon treatment, small subclones harboring NOTCH1 or BIRC3 mutations either shrank below the sensitivity threshold of our ultra-deep-NGS ( Figure 3 ; Figure 5S ) or persisted at low abundance, suggesting that they maintained sensitivity to chemotherapy and did not gain a competitive advantage over the wild type clones. This observation suggest that the enrichment of BIRC3 mutations that has been previously documented in advanced relapsed/refractory CLL 11 might be related to other factors contributing to the fitness of the clones harboring BIRC3 lesions, rather than a differential sensitivity to therapy. Small subclonal SF3B1 mutations were more frequently selected than counter-selected ( Figure 3 ; Figure 5S ). 
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SUPPLEMENTARY METHODS
Ultra-deep-NGS of NOTCH1, SF3B1 and BIRC3 Ultra-deep-NGS of the NOTCH1 (genomic region hg19 chr9:139390616-139390809; RefSeq NM_017617.2), SF3B1 (genomic regions hg19 chr2: 198267401-198267564, chr2:198267222-198267424, chr2:198266704-198266869 ; RefSeq NM_012433.2), and BIRC3 (genomic regions hg19 chr11:102201667-102201850, chr11:102201812-102201997, chr11:102207617-102207837; RefSeq NM_001165.3) mutation hotspots 1 was performed using the 454 chemistry and was based on amplicon libraries. Sequences for NOTCH1, SF3B1, and BIRC3 were retrieved from the UCSC Human Genome database using the corresponding mRNA accession number as a reference. Sequence specific PCR primers, located ~10 bp upstream or downstream to target exon boundaries were designed in the Primer 3 program (http://frodo.wi.mit.edu/primer3/) and filtered using UCSC in silico PCR to exclude pairs yielding more than a single product. In total, NOTCH1, SF3B1, BIRC3 regions of interest were covered by 7 sequence specific primer pairs, each flanked by MID-labeled Primer A and Primer B sequences to barcode the samples. In each ultra-deep-NGS experiment, a total of 63 amplicons, corresponding to NOTCH1, SF3B1, BIRC3 regions of interest of 9 distinct patients, were amplified from genomic DNA by using a high fidelity Taq polymerase (FastStart High fidelity PCR System, Roche Diagnostics). PCR products were then individually purified using Agencourt AMPure XP beads (Beckman Coulter) and quantified using the Quant-iT PicoGreen dsDNA kit (Invitrogen). Corresponding patient-specific amplicon pools were generated by combining each of the amplicons in an equimolar ratio for each patient sample. The pools were diluted to a concentration of 1×10 6 molecules per μl and processed using the GS Junior Series Lib-A method (Roche Diagnostics). Forward (A beads) and reverse (B beads) reactions were carried out using 5,000,000 beads per emulsion oil tube. The copy per bead ratio used was 1.1:1. The amplification reaction, breaking of the emulsions and enrichment of beads carrying amplified DNA were performed using the workflow as recommended by the manufacturer. Finally, the obtained amplicon library was loaded on a PicoTiterPlate (PTP) and subjected to ultra-deep-NGS on the Genome Sequencer Junior instrument (454 Life Sciences).
Bioinformatic approach to call subclonal NOTCH1, SF3B1, and BIRC3 variants out of the background error noise
The following bioinformatic workflow was established to call subclonal NOTCH1, SF3B1, and BIRC3 variants from ultra-deep-NGS experiments in patient samples. 2 First, for each patient, the sequencing reads were mapped to the reference genome hg19 using the Burrows-Wheeler Aligner (BWA) long-read alignment tool, and sites that differed from the reference NOTCH1, SF3B1, or BIRC3 sequence were identified. Variants overlapping the primers or neighboring them by one nucleotide, and variants mapping within homopolymeric tracts (for SF3B1 and BIRC3), that specifically suffer from errors in 454 NGS, were excluded from the analysis. To fit for the parameters of the negative binomial distribution, we used the remaining variants with a mean quality phred score >27 and a frequency <0.05. After correcting for multiple hypotheses according to the Bonferroni test, we obtained error distributions and depth thresholds for the discovery of true missense substitutions, deletions, and insertions. Next, we obtained error distributions and depth thresholds (without a multiple hypothesis correction) for the identification of each discovered significant variant, after excluding them from those used for fitting of the parameters. Finally, a list of variants that passed the discovery and identification depth thresholds was created.
Allele-specific PCR Separate AS-PCR was designed for each subclonal NOTCH1, SF3B1, and BIRC3 variant, and the assay was tailored at a sensitivity of 10 -3 (i.e detection of one mutant allele/1000 wild type alleles). As AS-PCR positive controls, pGEM-NOTCH1, pGEM-SF3B1, and pGEM-BIRC3 plasmids containing each one of the subclonal NOTCH1, SF3B1, and BIRC3 variants were generated by site directed mutagenesis. 2 Briefly, genomic DNA was isolated from healthy donor PBMC and NOTCH1 (genomic region hg19 chr9:139390616-139390809), SF3B1 (genomic regions hg19 chr2: 198267401-198267564, chr2:198267222-198267424, chr2:198266704-198266869) , and BIRC3 (genomic regions hg19 chr11:102201667-102201850, chr11:102201812-102201997, chr11:102207617-102207837) were amplified using a high fidelity Taq polymerase (Pfu DNA polymerase, Promega). NOTCH1, SF3B1, and BIRC3 amplicons were subjected to Sanger sequencing to rule out clonal mutations. NOTCH1, SF3B1, and BIRC3 amplicons were then cloned into the pGEM vector. Primers containing the index NOTCH1, SF3B1, and BIRC3 variant were used to introduce the variant into the pGEM-NOTCH1, pGEM-SF3B1, and pGEM-BIRC3 plasmids by high fidelity circular PCR amplification (Pfu DNA polymerase, Promega). pGEM-NOTCH1, pGEM-SF3B1, and pGEM-BIRC3 plasmids were then transformed into JM109 competent E. coli cells for high-yield plasmid production. The introduction of the index NOTCH1, SF3B1, and BIRC3 mutation into the pGEM-NOTCH1, pGEM-SF3B1, and pGEM-BIRC3 plasmids was confirmed by Sanger sequencing. Wild type NOTCH1 (genomic region hg19 chr9:139390616-139390809), SF3B1 (genomic regions hg19 chr2: 198267401-198267564, chr2:198267222-198267424, chr2:198266704-198266869 3) genes were analyzed by PCR amplification and Sanger sequencing of high molecular weight genomic DNA. All PCR primers and conditions are available upon request. Purified amplicons were subjected to conventional DNA Sanger sequencing using the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems), and compared to the corresponding germline sequences using the Mutation Surveyor Version 4.0.5 software package (SoftGenetics) after automated and/or manual curation. Of the evaluated sequences, 99% had a Phred score of 20 or more and 97% had a score of 30 or more. Candidate variants were confirmed from both strands on independent PCR products. The following databases were used to exclude known germline variants: Human dbSNP Database at NCBI (Build 136) (http://www.ncbi.nlm.nih.gov/snp); Ensembl Database (http://www.ensembl.org/index.html); The 1000 Genomes Project (http://www.1000genomes.org/); five single-genome projects available at the UCSC Genome Bioinformatics resource (http://genome.ucsc.edu/). Synonymous variants, previously reported germline polymorphisms and changes present in the matched normal DNA were removed from the analysis.
TP53 mutation analysis
Mutation analysis of the TP53 gene was performed by ultra-deep-NGS as previously described. 
IGHV-IGHD-IGHJ rearrangement analysis
PCR amplification of IGHV-IGHD-IGHJ rearrangements was performed on HMW genomic DNA using IGHV leader primers or consensus primers for the IGHV FR1 along with appropriate IGHJ genes, as previously described.
3 PCR products were directly sequenced with the BigDye Terminator v1.1 Ready Reaction Cycle Sequencing kit (Applied Biosystems) using the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). Sequences were analyzed using the IMGT databases and the IMGT/V-QUEST tool (version 3.2.17, Université Montpellier 2, CNRS, LIGM, Montpellier, France).
Fluorescence in situ hybridization (FISH)
Probes used for FISH analysis were: i) LSID13S319 (13q14 deletion), CEP12 (trisomy 12), LSIp53 (17p13/TP53 deletion), and LSIATM (11q2-q23/ATM deletion) (Abbott, Rome, Italy); and ii) the RP11-177O8 (BIRC3) BAC clone.
The labeled BAC probe was tested against normal control metaphases to verify the specificity of the hybridization. For each probe, at least 400 interphase cells with well-delineated fluorescent spots were examined. Nuclei were counterstained with 4',6'-diamidino-2-phenylindole (DAPI) and antifade reagent, and signals were visualized using an Olympus BX51 microscope (Olympus Italia, Milan, Italy). The presence of 13q14 deletion, trisomy 12, 11q22-q23 deletion, 17p13 deletion, and BIRC3 deletion was scored when the percentage of nuclei with the abnormality was above our internal cut off (5%, 5%, 7%, 10%, and 10% respectively), defined as the mean plus 3 standard deviations of the frequency of normal control cells exhibiting the abnormality.
Proportional hazard regression
The proportional hazard assumption was assessed by plotting the smoothed Schoenfeld residuals against time. 4 Possible interactions were tested as reported. 5 The bias corrected c-index and calibration slope of the Cox model were calculated through the .632 bootstrap method (1000 resamplings). [5] [6] [7] [8] The heuristic shrinkage estimator was calculated using the formula (model likelihood ratio χ 2 ) -(number of degree of freedom in the model)/(model likelihood ratio χ 2 ). This approach provides an estimate of prediction accuracy of the Cox model to protect against overfitting. 
Statistical power
The statistical power of the sample size was calculated by using the Cox.NIS of the TrialSize (v1.3) package of R. Figure 5S 
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